Perrigo Co Plc Stock Price, News & Analysis

Perrigo (NYSE: PRGO), a leading global self-care company, has declared a quarterly dividend of $0.290 per share. The dividend will be payable on September 16, 2025, to shareholders of record on August 29, 2025.

The company, with over a century of experience, specializes in over-the-counter (OTC) self-care products in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

[ "Consistent dividend payment demonstrates financial stability", "Strong market presence with century-long experience in self-care products", "Diversified portfolio combining private label and branded products" ]

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12th at 9:00 AM EDT.

The company, a pioneer in the over-the-counter (OTC) self-care market, has over a century of experience providing health and wellness solutions in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has scheduled the release of its second quarter 2025 financial results for Wednesday, August 6th, 2025. The company will host a conference call at 8:30 A.M. (EST) to discuss the results.

Perrigo is a pure-play self-care company specializing in over-the-counter (OTC) health and wellness solutions in North America and Europe. Their business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.

Perrigo (NYSE: PRGO) has announced an agreement to sell its Dermacosmetics branded business to KKR-managed Kairos Bidco AB for up to €327 million. The deal includes €300 million in upfront cash and up to €27 million in potential milestone payments tied to net sales performance over three years.

The transaction, expected to close in Q1 2026, is part of Perrigo's 'Three-S' strategic plan to Stabilize, Streamline, and Strengthen the organization. The divested brands include ACO, Biodermal, Emolium, and Iwostin, which generated approximately €125 million in net sales and about 5% of Perrigo's 2024 adjusted operating income.

Proceeds will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet. The deal remains subject to regulatory approvals and works council consultation.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced a strategic organizational restructuring to optimize its global Category-Led, Market Activation Growth Model. The company is making key leadership changes, with Roberto Khoury appointed as EVP & Chief Commercial Officer to lead global market activation, while Triona Schmelter, EVP & President of Consumer Self-Care Americas (CSCA), will depart the organization.

The reorganization aims to enhance agility, accelerate innovation, and drive sustainable growth as part of Perrigo's multi-year Stabilize, Streamline and Strengthen ('Three-S') plan. The company will centralize its global brand-building capabilities while maintaining market-empowered activation and commercial excellence. The restructuring will not impact Perrigo's full-year 2025 adjusted EPS guidance or reporting segments.

The implementation will occur over the coming months, following all required legal consultation processes. The roles of EVP and President CSCI and EVP and President CSCA will be discontinued as part of this organizational alignment.

Perrigo (NYSE:PRGO), through its Good Start® | Dr. Brown's™ brand, has announced a nationwide giveaway contest starting July 1, 2025. The month-long contest will select 100 winners who will each receive a two-month supply of Gentle Pro™ baby formula along with Dr. Brown's products, valued at $516.49 per winner.

Alongside the contest, the company is making a significant charitable contribution to Baby2Baby, donating over 4,000 cans of Gentle Pro™ formula plus Dr. Brown's products, supporting over 95,000 feedings with a total donation value exceeding $85,000. The combined contest and donation initiative has an approximate retail value of $139,071.

The contest runs through July with winners to be announced by August 6th. Gentle Pro™, described as the company's closest formula to breastmilk, features gut-friendly probiotics and 100% whey proteins, designed for babies with sensitive tummies.

Perrigo (NYSE: PRGO) announced a leadership transition in its global operations and supply chain, with Matt Winterman appointed as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. He succeeds Ron Janish, who will retire on September 30, 2025, after over 20 years with the company. Winterman brings more than 20 years of experience, most recently serving as SVP of Global Supply Chain and Strategy at AstraZeneca, where he managed a $54 billion supply chain across 5,000 SKUs. Janish's tenure was marked by significant achievements in supply chain transformation and maintaining operational resilience during COVID-19. The transition will involve both executives working together to ensure continuity in Perrigo's operations and advancement of its consumer self-care strategy.

Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the virtual Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference on June 10 at 9 AM ET.

Perrigo is a pure-play self-care company operating primarily in North America and Europe, specializing in over-the-counter (OTC) healthcare products. The company's business model combines store brand private label offerings with branded products including Opill®, Mederma®, Compeed®, EllaOne®, and Solpadeine®.

Perrigo (PRGO) reported Q1 2025 financial results showing mixed performance. Net sales declined 3.5% to $1.04 billion, primarily due to divested businesses and currency impacts. Despite the sales decline, the company demonstrated significant profitability improvements with adjusted operating income increasing 57.6% to $147 million and adjusted EPS growing 106.9% to $0.60. The company's infant formula business showed strong recovery with 16% growth in the Nutrition category. Gross margins expanded substantially, with adjusted gross margin increasing 440 basis points to 41.0%. Due to macroeconomic uncertainty, Perrigo widened its 2025 net sales growth outlook to 0-3% from 1-3%, but reaffirmed other financial targets, including adjusted EPS guidance. The company's 'Project Energize' efficiency program has achieved approximately $159 million in gross annual savings with $20 million reinvested.